Trials / Unknown
UnknownNCT04838548
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
An Open-Label, Multi-Cohort, Multi-center, Non-Randomized, Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Shanghai Miracogen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG003 | Administered intravenously |
Timeline
- Start date
- 2020-09-04
- Primary completion
- 2022-12-01
- Completion
- 2023-02-01
- First posted
- 2021-04-09
- Last updated
- 2021-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04838548. Inclusion in this directory is not an endorsement.